MedTrace Logo

LDL Receptor Under Ezetimibe and Simvastatin

NCT00317993 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2014-12-03

No results posted yet for this study

Summary

The purpose of this study is to investigate the effects of the two lipid -lowering drugs, ezetimibe and simvastatin, on lipid metabolism in humans. In specific, the study will investigate in blood cells whether the enzyme that controls cholesterol synthesis, HMG-CoA reductase, and the receptor that takes up cholesterol from the blood, the LDL receptor, are changed during treatment with the aforementioned drugs.

Conditions

  • Healthy Men

Interventions

DRUG

ezetimibe

DRUG

simvastatin

DRUG

ezetimibe plus simvastatin

Sponsors & Collaborators

Principal Investigators

  • Ioanna Gouni-Berthold, MD · Medizinische Klinik II und Poliklinik für Innere Medizin

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2004-07-31
Completion
2004-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00317993 on ClinicalTrials.gov